Treatment of Bernard-Soulier Syndrome (BSS)

1. General Principles

• Care is generally supportive - most patients need no daily medications
• Antiplatelet drugs (aspirin, NSAIDs, P2Y12 inhibitors) must be strictly avoided - they worsen already-impaired platelet function
• Mild-to-moderate symptoms can often be managed with conservative and pharmacologic measures
• Severe or life-threatening bleeding requires platelet transfusion
• A pediatric or adult hematologist should be involved in all cases

2. Conservative / Local Measures

• Local pressure and topical hemostatics for surface or mucosal bleeding
• Nasal packing for epistaxis
• Restriction of high-risk activities in patients with moderate-to-severe symptoms (contact sports, activities prone to trauma)

3. Pharmacologic Treatments

A. Antifibrinolytic Agents (first-line for mucosal bleeding)

• Tranexamic acid or epsilon-aminocaproic acid (EACA) are the most widely used agents
• Indicated for mucosal bleeding (epistaxis, gingival, menorrhagia), dental procedures, and minor surgical prophylaxis
• Caution: avoid in hematuria (risk of clot in the urinary tract)
• Tranexamic acid 1 g three times daily (dose used in general hemorrhagic conditions)

B. Desmopressin (DDAVP)

• May shorten bleeding time in some (not all) BSS patients, particularly those with partial/residual GPIb expression
• Mechanism unclear - likely related to increased vWF binding to residual GPIb
• Useful for minor bleeding episodes and pre-procedure prophylaxis in mild cases
• Not universally effective; response should be tested before relying on it

C. Hormonal Therapy

• Combined oral contraceptives are a key treatment for heavy menstrual bleeding (menorrhagia) in females with BSS
• Intrauterine progestins are an alternative
• Often used as long-term maintenance to reduce cycle-associated bleeding burden

4. Platelet Transfusion

• The most effective intervention for active, significant bleeding and perioperative prophylaxis
• Indicated for: surgery, life-threatening hemorrhage, and major procedures
• Should be reserved for these situations due to risk of alloimmunization

Key Concern - Alloimmunization:

• Biallelic (classical) BSS patients completely lack GPIb/IX/V - transfused donor platelets carry this complex, which is foreign to the patient
• The immune system can develop anti-GPIb/IX/V alloantibodies, rendering future transfusions ineffective
• To minimize this risk:
  • Use leukoreduced (leukodepleted) platelet concentrates at all times
  • Use HLA-matched platelets whenever possible
  • Some pathogen-reduction techniques (e.g., riboflavin/UV treatment) may achieve comparable or better results

Managing Alloimmunization:

• Once isoimmunization occurs, immunosuppression and/or plasmapheresis may restore efficacy of platelet transfusions (Haematologica 2022)

5. Recombinant Activated Factor VIIa (rFVIIa)

• Use: When platelet transfusions are contraindicated, refused, or ineffective (especially in alloimmunized patients)
• Mechanism: activates the extrinsic coagulation pathway, enhancing thrombin generation and fibrin deposition at injury site, independent of GPIb
• Has been successfully used to cover major and minor surgery in biallelic BSS patients
• Administration schedule similar to that used in Glanzmann thrombasthenia
• Major risk: Thromboembolic events - use only when other options have failed
• Not formally approved for BSS; used off-label

6. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

• The only curative option available
• Indicated in refractory cases with severe, recurrent, life-threatening bleeding uncontrollable with other measures
• High procedural risk; reserved for the most severe cases
• Limited case reports support feasibility

7. Perioperative / Procedural Management

• Target platelet count ≥100 × 10⁹/L for major surgery
• For spinal/epidural anesthesia, platelet count >70 × 10⁹/L is generally required
• Biallelic BSS has the highest surgical bleeding risk among inherited platelet disorders - incidence of surgical bleeding ~44.4% in one international retrospective study
• Antifibrinolytics + platelet transfusion are typically combined for hemostatic coverage

8. Obstetric Considerations

• Women with BSS are at high risk for postpartum hemorrhage
• Neonates born to BSS mothers risk neonatal alloimmune thrombocytopenia (NAIT) if maternal alloantibodies cross the placenta
• Management during delivery requires coordination with hematology; platelet transfusion support and antifibrinolytics should be pre-planned

9. What to Avoid

Summary Table